The sources behind Sermorelin’s changing story
These links follow the same questions as the rest of the guide. Some explain the children’s treatment. Others cover adult studies or FDA decisions. Each belongs to a particular question; none gives a blanket answer about a prescription today.
Children’s studies and earlier use
The first-year growth study
Thorner and colleagues, 1996. Children with growth hormone deficiency grew faster. No untreated comparison group; final adult height wasn’t established.
The nasal pilot
Hümmelink and colleagues, 1993. Height growth didn’t speed up with the nasal preparation tested in this small children’s study.
The pediatric review
Prakash and Goa, 1999. Explains earlier uses and reports flushing and injection-site pain.
The children’s follow-up
Lanes and Carrillo, 1994. Antibodies appeared in some children without seeming to interfere with growth.
Adult studies and safety questions
The older-men hormone study
Corpas and colleagues, 1992. Hormone measurements changed during a short trial. This wasn’t proof of reversing aging.
The nightly adult study
Vittone and colleagues, 1997. Growth hormone rose overnight; measured muscle and fat didn’t change.
The tesamorelin thinking trial
Baker and colleagues, 2012. The medicine was tesamorelin, rather than Sermorelin. Its result can’t be transferred between drugs.
The absorption study
Wilton and colleagues, 1993. Tested intravenous and nasal forms in healthy men; nasal absorption was low.
The FDA’s growth hormone safety discussion
FDA, 2024. A review of related peptides discusses growth hormone label warnings, rather than measured adult Sermorelin risks.
Approvals and today’s prescription questions
The approval-withdrawal notice
FDA, 2009. Records the old approvals ending at their holders’ request.
The later FDA finding
FDA, 2013. Gives the approval history and finds no safety or effectiveness reason for leaving sale.
The FDA application records
FDA records show the former products as discontinued, with no current approved Sermorelin product.
The Orange Book files
FDA drug listings include the former product in the discontinued section.
The 503B category list
FDA, March 2025. Lists Sermorelin acetate under Category 1 and marks it as an approved-drug component.
The 503A category list
FDA, May 2026. Sermorelin doesn’t appear in these three categories. This is a different framework from 503B.
The 503A ingredient guidance
FDA, January 2025. Explains the approved-drug ingredient route, with other conditions still required.
FDA compounding questions and answers
Explains why a compounded medicine is not FDA-approved, even when it is prescribed.
FDA on compounding risks
Explains the absence of FDA checks for safety, effectiveness and quality before marketing.
Telehealth licensing
HHS guidance explains why the patient’s location matters for licensing.
Physician licensing records
The Federation of State Medical Boards explains public licence and disciplinary records.
State pharmacy boards
A directory of the state boards that license pharmacies.
What can a source answer?
A study can tell us what happened to the people who took part. Its result doesn’t automatically carry over to a different age group, medicine or way of giving it. The adult research page shows why those details matter.
Government records need the same care. The FDA’s finding about an old product leaving sale isn’t an approval of a new compounded one. The chronology follows those events in order, and the access page explains what they mean for a present prescription discussion.